BMO Capital Downgrades ZIOPHARM Oncology (ZIOP) to Market Perform
Tweet Send to a Friend
BMO Capital downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Outperform to Market Perform with a price target of $10.00 (from $15.00).Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


